Contingency management for smoking cessation among individuals with type 2 diabetes: Protocol for a multi-center randomized controlled feasibility trial

Tuesday, January 25th, 2022

This paper describes the design of a randomized controlled trial that will explore the feasibility of contingency management and biochemical verification using a remote smartphone-based carbon monoxide monitor for smoking cessation in patients with type 2 diabetes mellitus; in total, 60 patients will receive standard smoking cessation treatment (ie counseling and nicotine replacement therapy), with randomization to a short‑term financial incentive (6 weeks), a long‑term financial incentive (12 weeks), or no incentive. Patients will attend three clinic visits, at which time use of tobacco products will be assessed using the Vitalograph BreathCO monitor.